When Sequenom Inc. sought to wield its patent on a method for isolating fetal DNA in order to block rival prenatal diagnostic tests, one of its competitors, Ariosa Diagnostics Inc., tapped Irell & Manella’s David Gindler to challenge the patent’s validity.
Four years later, Gindler has secured three rulings in Ariosa’s favor, leaving Sequenom with only one option to try to salvage the patent—a long-odds trip to the U.S. Supreme Court.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
